Company Description
Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States.
It develops Rencofilstat, a cyclophilin inhibitor is in Phase 2b clinical trial to target multiple pathologic pathways involved in the progression of liver disease and treat non-alcoholic steatohepatitis (NASH), as well as preclinical studies of Rencofilstat shows reduction in liver fibrosis, liver inflammation, liver tumor burden, and titers of HBV, HCV, HDV, and HIV-1, and has demonstrated antiviral activities for hepatitis B, C, and D viruses through several mechanisms.
The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019.
Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.
| Country | United States |
| Founded | 2013 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 22 |
| CEO | John Brancaccio |
Contact Details
Address: 399 Thornall Street, First Floor Edison, New Jersey 08837 United States | |
| Phone | 732 902 4000 |
| Website | hepionpharma.com |
Stock Details
| Ticker Symbol | HEPA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001583771 |
| CUSIP Number | 426897104 |
| ISIN Number | US4268973025 |
| Employer ID | 46-2783806 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| John Patrick Brancaccio CPA | Interim Chief Executive Officer, Interim Chief Financial Officer and Chairman of the Board |
| Sharen Pyatetskaya | Director of Investor Relations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 14, 2024 | 10-Q | Quarterly Report |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Sep 5, 2024 | 425 | Filing |
| Sep 5, 2024 | 8-K | Current Report |
| Aug 13, 2024 | 10-Q | Quarterly Report |
| Aug 7, 2024 | 425 | Filing |
| Aug 7, 2024 | 8-K | Current Report |
| Jul 24, 2024 | D | Notice of Exempt Offering of Securities |
| Jul 22, 2024 | 425 | Filing |
| Jul 22, 2024 | 8-K | Current Report |